How Much Does Digital Therapeutics App Development Cost 2026?

Digital therapeutics is not just another health app category. When you build a DTx product, you are building software that the FDA treats as a medical device. That changes everything about scope, timeline, and budget. The DTx market is projected to reach $13.5 billion by 2028, growing at a 26% CAGR, and the FDA approved 6 new prescription digital therapeutics in 2025 and 2026 alone. There is genuine commercial opportunity here, but the cost of entry is significantly higher than a typical wellness app.

We have built regulated health products for startups pursuing FDA clearance, for pharma companies launching companion DTx apps, and for clinical research teams spinning out university IP into commercial software. The budgets vary enormously depending on your regulatory pathway, your clinical evidence requirements, and whether you are building a standalone therapy or a complement to an existing drug.

Here are the three tiers we use when scoping digital therapeutics projects:

• Tier 1: Research Prototype / Non-Prescription DTx with therapeutic content delivery, basic outcome tracking, and HIPAA-compliant data collection. No FDA submission. Budget: $150,000 to $350,000.
• Tier 2: FDA 510(k) Cleared DTx with a therapeutic protocol engine, clinician dashboard, patient outcome tracking, EHR integration, and a completed regulatory submission. Budget: $500,000 to $1,200,000.
• Tier 3: Prescription DTx with Full Clinical and Commercial Stack including randomized controlled trial integration, ePrescribing via HL7 FHIR, payer integration, clinician portals, and post-market surveillance. Budget: $1,000,000 to $2,500,000+.

These ranges assume a US-based regulatory and clinical team, a blended development team (US leads with nearshore engineers), React Native or native mobile apps, and cloud infrastructure on AWS GovCloud or a HIPAA-eligible GCP environment. If you have already completed your clinical trial and have a predicate device for a 510(k), you can shave 20 to 30 percent off the Tier 2 numbers. If you are pursuing a De Novo classification because no predicate exists, add 30 to 50 percent to account for the longer and more complex regulatory process.

The single largest variable in your DTx budget is which FDA pathway you pursue. This is the decision that separates a $300,000 project from a $2,000,000 one. Let me break down the three main options and what each actually costs in practice.

510(k) Premarket Notification

The 510(k) is the most common pathway for digital therapeutics. You demonstrate that your software is "substantially equivalent" to an already-cleared predicate device. Pear Therapeutics used this pathway for reSET (substance use disorders), and several recent DTx clearances have followed the same route. The FDA review timeline is typically 3 to 6 months after submission, but preparing the submission itself takes 4 to 8 months of regulatory work.

Cost breakdown for a 510(k) submission:

• Regulatory consultant or in-house RA team: $80,000 to $200,000. You need someone who has filed Software as a Medical Device (SaMD) submissions before. Firms like Emergo by UL, MCRA, and Greenlight Guru's consulting arm specialize in this. Do not try to do this with a generalist regulatory consultant who mostly handles hardware devices.
• Software documentation (IEC 62304 compliance): $30,000 to $80,000. The FDA requires your software development lifecycle to follow IEC 62304, which means documented requirements, architecture specs, unit testing, integration testing, traceability matrices, and risk analysis per ISO 14971. This is engineering documentation work that runs parallel to your actual development.
• Clinical evidence package: $50,000 to $300,000. Depending on your predicate and your therapeutic claims, you may need a clinical study or you may get by with a literature review and bench testing. More on this in the clinical trial section.
• FDA user fee: Approximately $21,000 for the standard 510(k) fee in 2026 (small business fee is lower at roughly $5,200).
• Quality Management System (QMS): $20,000 to $50,000 to set up an FDA-compliant QMS. Tools like Greenlight Guru, MasterControl, or Qualio can reduce this, but you still need SOPs, CAPA processes, design controls, and document management configured and validated.

De Novo Classification

If no predicate device exists for your DTx product, you will need the De Novo pathway. This is what Akili Interactive used for EndeavorRx (ADHD treatment through a video game). The De Novo process is longer and more expensive because you are essentially asking the FDA to create a new regulatory classification for your type of product.

De Novo adds roughly $150,000 to $400,000 on top of your 510(k) costs, primarily because of a more extensive clinical evidence requirement, longer FDA review cycles (6 to 12 months), and the need for more robust post-market surveillance planning. The FDA user fee for De Novo is also higher, around $130,000 for standard submissions in 2026.

FDA Enforcement Discretion / Exempt Pathway

Some digital health products fall under the FDA's enforcement discretion guidance, meaning the FDA acknowledges the product meets the definition of a medical device but chooses not to enforce premarket review requirements. Low-risk wellness products, clinical decision support tools, and certain general wellness apps may qualify. If your DTx product genuinely qualifies for this pathway, you can skip the $200,000+ regulatory submission process entirely. But be very careful here. If your product makes therapeutic claims and delivers a clinical intervention, you almost certainly need a 510(k) or De Novo, regardless of what your competitor is doing.

The therapeutic protocol engine is the heart of a digital therapeutics app. Unlike a wellness app where content is informational, a DTx product delivers structured, evidence-based interventions that are clinically validated to treat specific conditions. Building this correctly is both technically complex and clinically sensitive.

Protocol Engine Architecture

A therapeutic protocol engine manages the sequencing, branching, and dosing of therapeutic content. Think of it as the logic layer that decides what a patient sees, when they see it, and how the program adapts based on their responses and progress. For a CBT-based DTx (like those targeting substance use disorders or insomnia), the engine needs to handle multi-week treatment protocols with branching paths, adaptive difficulty, and clinician-overridable parameters.

Building a flexible protocol engine costs $40,000 to $120,000 depending on complexity. A simple linear protocol with fixed content sequencing is on the low end. A fully adaptive engine that adjusts therapeutic modules based on real-time patient outcome data, clinician inputs, and adherence patterns is on the high end. We typically recommend building the engine as a rules-based system with a configuration layer so that clinical teams can modify protocols without requiring code changes. This adds $15,000 to $30,000 upfront but saves enormous amounts of iteration time during clinical validation.

Patient-Facing Therapeutic Content

The actual therapeutic content (lessons, exercises, interactive modules, videos, guided activities) requires clinical authoring, instructional design, and multimedia production. Budget $30,000 to $80,000 for a full treatment program of 8 to 12 weeks. This cost covers clinical psychologist authoring, UX design for therapeutic interactions, illustration or animation, and audio production if your protocol includes guided exercises.

Do not underestimate this line item. The content is your product. Pear Therapeutics spent years refining their CBT content with clinical researchers before commercializing. Your therapeutic content needs to be authored by licensed clinicians, reviewed by your clinical advisory board, and validated through your clinical evidence process.

Patient Outcome Tracking

Every DTx product needs robust patient outcome measurement. This includes validated clinical instruments (PHQ-9 for depression, GAD-7 for anxiety, AUDIT for alcohol use, PCL-5 for PTSD), patient-reported outcomes (PROs), adherence metrics, and longitudinal trend analysis. Building a comprehensive outcome tracking system with automated scoring, trend visualization, and data export for clinical research costs $25,000 to $60,000.

The tracking system also needs to support the data collection requirements of your clinical trial if you are running one concurrently. That means eCRF (electronic case report form) integration, audit trails, and potentially 21 CFR Part 11 compliance for electronic signatures and records. This regulatory data layer adds another $15,000 to $40,000.

Digital therapeutics apps handle some of the most sensitive health data imaginable: psychiatric assessments, substance use history, treatment adherence records, and clinical outcome measures. The compliance and integration requirements are significantly more demanding than a typical healthcare app.

HIPAA-Compliant Infrastructure

We have covered HIPAA compliance costs in detail elsewhere, but for DTx specifically, you need to plan for a more rigorous implementation than a standard health app. Because your software is classified as a medical device, your data handling practices will be scrutinized during FDA review. Expect $30,000 to $75,000 for HIPAA infrastructure setup, including encrypted storage on AWS GovCloud or HIPAA-eligible GCP, BAA agreements with every vendor in your data chain, audit logging for all PHI access, role-based access controls, and breach notification procedures.

Ongoing HIPAA monitoring runs $1,500 to $3,000 per month through platforms like Vanta, Drata, or Secureframe. For a DTx product, I strongly recommend automated compliance monitoring from day one because your FDA QMS audits will also review your data handling practices.

EHR Integration via HL7 FHIR

Prescription digital therapeutics need to integrate with the clinical workflow. That means exchanging data with electronic health record systems like Epic, Cerner (now Oracle Health), and Athenahealth. The industry standard is HL7 FHIR (Fast Healthcare Interoperability Resources), and most major EHRs now support FHIR R4 APIs.

A single EHR integration via FHIR costs $30,000 to $80,000 depending on the scope of data exchange. If you are sending treatment outcomes back to the prescribing clinician's EHR, you need to map your data to FHIR resources (Observation, CarePlan, MedicationRequest), handle authentication via SMART on FHIR, and pass the EHR vendor's app marketplace review process. Epic's App Orchard review alone takes 2 to 4 months and requires a dedicated effort.

Each additional EHR integration adds $20,000 to $50,000. Most DTx companies start with Epic (largest market share in the US hospital market) and add Cerner and Athenahealth in subsequent phases.

ePrescribing Integration

For prescription digital therapeutics, clinicians need to prescribe your product through their existing ePrescribing workflow, just like they would prescribe a medication. This requires integration with ePrescribing networks like Surescripts. The patient receives a "prescription" that grants them access to your DTx product, and the prescribing event is recorded in their medical record.

Building ePrescribing support costs $40,000 to $100,000. You need to register your product with the relevant drug databases (FDA NDC equivalent for digital products), integrate with Surescripts or a similar network, build prescription verification and activation flows in your app, and handle prescription renewals and expiration. This is one of the most underestimated costs in DTx development because it involves coordination with multiple external systems and stakeholders.

You cannot build a credible digital therapeutic without clinical evidence. The FDA expects it. Payers demand it before they will cover your product. And clinicians will not prescribe something without published data. The cost of generating that evidence is a major part of your overall DTx budget.

Randomized Controlled Trials (RCTs)

A pivotal RCT for a digital therapeutic typically enrolls 150 to 400 participants across multiple sites and runs 12 to 24 weeks. The software needs to support randomization, blinding (where applicable), data collection, adverse event reporting, and regulatory-grade audit trails. The clinical operations cost of running the trial (site management, IRB approvals, participant recruitment, data monitoring) is separate from the software cost, but the software must be purpose-built to support the trial protocol.

Building clinical trial support into your DTx platform costs $60,000 to $150,000. This includes randomization engines, eCRF data collection compliant with 21 CFR Part 11, electronic consent (eConsent) workflows, adverse event capture and reporting, data export in CDISC format for FDA submission, and integration with your clinical data management system (CDMS). If you are using a third-party EDC (electronic data capture) platform like Medidata Rave, REDCap, or Veeva Vault CDMS, the integration work is $20,000 to $50,000 instead of building from scratch.

The clinical trial itself (excluding software) typically costs $500,000 to $3,000,000 depending on the number of sites, enrollment targets, and study duration. This is separate from your software development budget, but it is critical context for your overall fundraising plan.

Real-World Evidence and Post-Market Studies

After FDA clearance, you need ongoing evidence generation to support payer negotiations and clinical adoption. Building real-world evidence (RWE) collection into your production app costs $20,000 to $50,000 on top of your existing outcome tracking system. This includes anonymized data aggregation, outcomes reporting dashboards for your medical affairs team, and data export for health economics and outcomes research (HEOR) studies.

Payers like UnitedHealthcare, Aetna, and Cigna increasingly require DTx companies to demonstrate real-world outcomes before granting formulary coverage. Having this data infrastructure built in from launch puts you months ahead of competitors who try to retrofit it later.

Building the patient-facing DTx app is only half the product. You also need a clinician-facing portal, a payer integration layer, and commercial infrastructure to actually get your product prescribed, reimbursed, and used in clinical practice.

Clinician Dashboard

Prescribing clinicians need to monitor their patients' engagement with your DTx product. A clinician dashboard typically includes patient enrollment and activation status, treatment adherence metrics (sessions completed, time spent, module progress), clinical outcome trends with validated instruments, alerts for non-adherence or concerning responses, and the ability to adjust treatment parameters or send messages to patients.

Building a production-quality clinician dashboard costs $40,000 to $100,000. Do not treat this as an afterthought. If clinicians find your dashboard clunky or time-consuming, they will stop prescribing your product. We have seen DTx startups lose major health system contracts because their clinician experience was an MVP while their patient app was polished.

Payer and Pharmacy Benefit Manager Integration

Getting insurance coverage for your DTx product is essential for commercial viability. This involves contracting with pharmacy benefit managers (PBMs) like CVS Caremark, Express Scripts, and OptumRx, and integrating with their adjudication systems so that prescriptions can be filled and reimbursed through existing pharmacy workflows.

The technical integration with PBM systems costs $30,000 to $80,000. But the real cost is the 6 to 18 months of negotiation, formulary review, and outcomes data sharing that precedes the technical work. Budget for a dedicated market access team or consultant ($10,000 to $30,000 per month) to manage these relationships.

Commercial Analytics and Post-Market Surveillance

Once your DTx product is on the market, you need robust analytics for three audiences: your internal team (product metrics, engagement funnels, retention), your clinical/regulatory team (adverse event monitoring, complaint handling, post-market surveillance per FDA requirements), and your commercial team (prescriber adoption, fill rates, payer coverage rates). Building this analytics stack costs $25,000 to $60,000 using tools like Mixpanel or Amplitude for product analytics, combined with custom dashboards for clinical and commercial metrics.

FDA post-market surveillance is not optional for SaMD products. You need a system to capture, investigate, and report adverse events and software-related complaints. Building a compliant complaint handling and adverse event reporting system costs $15,000 to $40,000, and it needs to integrate with your QMS.

Digital therapeutics development is a marathon. Unlike a SaaS product where you can go from idea to launch in 3 to 4 months, a prescription DTx product typically takes 18 to 36 months from concept to FDA clearance and commercial launch. Here is what the timeline looks like at each tier.

Typical Development Timelines

• Tier 1 (Research Prototype): 4 to 6 months with a team of 3 to 4 developers, 1 designer, a clinical advisor, and a PM. This gets you a functional therapeutic app suitable for pilot studies.
• Tier 2 (FDA 510(k) Cleared DTx): 12 to 20 months total. 4 to 6 months for core development, 4 to 8 months for regulatory documentation and submission preparation, and 3 to 6 months for FDA review. Team: 4 to 6 developers, 1 to 2 designers, a QA engineer, a regulatory affairs specialist, a clinical lead, and a PM.
• Tier 3 (Full Prescription DTx Platform): 18 to 36 months. Includes concurrent clinical trial execution, which is the longest pole in the tent. Team: 6 to 10 developers, 2 designers, 2 QA engineers, a regulatory affairs team, a clinical operations team, a medical affairs lead, DevOps/SRE, and a PM.

Monthly Ongoing Costs After Launch

• Cloud hosting (AWS GovCloud/HIPAA-eligible): $2,000 to $15,000 per month depending on user volume and data storage requirements.
• QMS and compliance tools: Greenlight Guru ($1,000 to $3,000/month), Vanta ($1,500 to $2,500/month).
• EHR and ePrescribing network fees: $2,000 to $10,000 per month depending on transaction volume.
• Maintenance and updates: Budget 20 to 25 percent of initial build cost annually. FDA-regulated software requires a disciplined change control process, so even minor updates involve documentation and risk analysis.
• Clinical and regulatory staff: At minimum, a part-time regulatory affairs consultant ($5,000 to $15,000/month) and clinical oversight ($3,000 to $10,000/month) for ongoing post-market obligations.

Funding Considerations

Most DTx startups raise $3 to $10 million in Series A funding to cover software development, clinical trials, and initial commercialization. If you are pre-seed or seed stage, focus on Tier 1 (a research prototype with pilot study data) to de-risk the clinical hypothesis before raising a larger round for regulatory clearance. Companies like Akili, Pear, and Freespira all followed this staged approach.

The digital therapeutics market is real and growing fast. But this is not a space where you can ship an MVP in 8 weeks and iterate your way to product-market fit. The regulatory, clinical, and commercial requirements demand careful planning and realistic budgeting from day one.

At Kanopy Labs, we have built regulated health products, HIPAA-compliant platforms, and clinical-grade software for teams at every stage. If you are exploring a digital therapeutics product and want an honest assessment of what it will take to build, clear FDA, and launch commercially, we are happy to walk through it with you.

Book a free strategy call and let's map out the real cost of bringing your DTx product to market.